INTS icon

Intensity Therapeutics

0.3451 USD
-0.0151
4.19%
At close Updated Feb 4, 4:00 PM EST
Pre-market
After hours
0.3489
+0.0038
1.1%
1 day
-4.19%
5 days
-9.18%
1 month
-12.85%
3 months
-35.5%
6 months
29.93%
Year to date
-15.21%
1 year
-84.73%
5 years
-94.21%
10 years
-94.21%
 

About: Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Employees: 16

0
Funds holding %
of 7,550 funds
Analysts bullish %
Positive news %
Price charts implemented using Lightweight Charts™